This article was originally published in The Gray Sheet
Hologic and Cohesion Technologies are among the latest to initiate stock repurchase programs in the wake of volatility in the broader market. Bone densitometry firm Hologic and surgical sealant developer Cohesion both plan to repurchase up to 1 mil. shares. Other firms announcing stock repurchase programs include Biosite Diagnostics (1 mil. shares); Chronimed (1 mil. shares); Respironics (1 mil. shares); Perclose (500,000 shares); Ventana Medical Systems (750,000 shares); and Bionx Implants (unspecified). Safeskin's 2 mil. share repurchase program is 75% complete
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.